Kiora Pharmaceuticals Stock Fundamentals
| KPRX Stock | USD 0.49 0.02 3.92% |
Kiora Pharmaceuticals fundamentals help investors to digest information that contributes to Kiora Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Kiora Stock. The fundamental analysis module provides a way to measure Kiora Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kiora Pharmaceuticals stock.
At this time, Kiora Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Other Operating Expenses is likely to rise to about 10 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 59.3 K in 2024. Kiora | Select Account or Indicator |
Kiora Pharmaceuticals Company Return On Asset Analysis
Kiora Pharmaceuticals' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Kiora Pharmaceuticals Return On Asset | -0.34 |
Most of Kiora Pharmaceuticals' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kiora Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Kiora Total Assets
Total Assets |
|
Based on the latest financial disclosure, Kiora Pharmaceuticals has a Return On Asset of -0.3354. This is 96.17% lower than that of the Biotechnology sector and 98.58% lower than that of the Health Care industry. The return on asset for all United States stocks is 139.57% higher than that of the company.
Kiora Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Kiora Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Kiora Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kiora Pharmaceuticals competition to find correlations between indicators driving Kiora Pharmaceuticals's intrinsic value. More Info.Kiora Pharmaceuticals is rated below average in return on equity category among related companies. It is rated second overall in return on asset category among related companies . At this time, Kiora Pharmaceuticals' Return On Equity is fairly stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Kiora Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Kiora Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kiora Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Kiora Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kiora Pharmaceuticals' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kiora Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kiora Pharmaceuticals by comparing valuation metrics of similar companies.Kiora Pharmaceuticals is currently under evaluation in return on asset category among related companies.
Kiora Fundamentals
| Return On Equity | -1.43 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | 10.53 M | ||||
| Shares Outstanding | 26.26 M | ||||
| Shares Owned By Insiders | 0.86 % | ||||
| Shares Owned By Institutions | 17.60 % | ||||
| Number Of Shares Shorted | 49.53 K | ||||
| Price To Book | 2.47 X | ||||
| Price To Sales | 535.59 X | ||||
| Gross Profit | (5.14 M) | ||||
| EBITDA | (8.63 M) | ||||
| Net Income | (12.51 M) | ||||
| Cash And Equivalents | 2.43 M | ||||
| Cash Per Share | 2.64 X | ||||
| Total Debt | 106.89 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 1.53 X | ||||
| Book Value Per Share | 0.79 X | ||||
| Cash Flow From Operations | (9.56 M) | ||||
| Short Ratio | 0.26 X | ||||
| Earnings Per Share | (2.69) X | ||||
| Target Price | 3.67 | ||||
| Number Of Employees | 12 | ||||
| Beta | -0.26 | ||||
| Market Capitalization | 12.87 M | ||||
| Total Asset | 13.71 M | ||||
| Retained Earnings | (146.98 M) | ||||
| Working Capital | 3.1 M | ||||
| Net Asset | 13.71 M |
About Kiora Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kiora Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiora Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiora Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 3.1 M | 4.9 M | |
| Total Revenue | 12.1 K | 0.0 | |
| Cost Of Revenue | 62.4 K | 59.3 K | |
| Stock Based Compensation To Revenue | 54.02 | 56.72 | |
| Sales General And Administrative To Revenue | 347.70 | 365.08 | |
| Research And Ddevelopement To Revenue | 266.14 | 279.45 | |
| Capex To Revenue | (12.76) | (12.12) | |
| Revenue Per Share | 0.12 | 0.11 | |
| Ebit Per Revenue | (780.98) | (741.93) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Kiora Pharmaceuticals Piotroski F Score and Kiora Pharmaceuticals Altman Z Score analysis. For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for Kiora Stock analysis
When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
Is Kiora Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiora Pharmaceuticals. If investors know Kiora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiora Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.69) | Revenue Per Share 0.002 | Return On Assets (0.34) | Return On Equity (1.43) |
The market value of Kiora Pharmaceuticals is measured differently than its book value, which is the value of Kiora that is recorded on the company's balance sheet. Investors also form their own opinion of Kiora Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiora Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiora Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiora Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiora Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiora Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiora Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.